News

December 11, 2020December 11, 2020

Yescarta Shows Promise in Advanced Non-Hodgkin Lymphomas, Trial Data Show

News

Yescarta (axicabtagene ciloleucel), Kite Pharma’s CAR T-cell therapy, leads to a high rate of strong and sustained responses in adults with relapsed or refractory (resistant) follicular lymphoma, known as FL, or marginal zone ... Read more

December 9, 2020December 9, 2020

Tislelizumab Safely Prolongs Survival in Advanced Lung Cancer Patients, Interim Data Show

News

When given as a second- or third-line therapy, BeiGene’s tislelizumab is superior to docetaxel at prolonging the survival of people with locally advanced or metastatic non-small cell lung cancer (NSCLC), ... Read more

December 7, 2020December 7, 2020

FDA Approves Less Frequent Treatment Regimen for Imfinzi in NSCLC, Bladder Cancer

News

The U.S. Food and Drug Administration (FDA) has approved a new dosing regimen for Imfinzi (durvalumab) for the treatment of certain non-small cell lung cancer (NSCLC) and bladder cancer patients. Granted under priority review, ... Read more

December 4, 2020December 4, 2020

Keytruda-Lenvima Combo in Kidney Cancer Better Than Sutent in Improving Survival

News

A combination of Keytruda (pembrolizumab) and Lenvima (lenvatinib) worked better than standard Sutent (sunitinib) in improving survival outcomes among adults with untreated advanced renal cell carcinoma (RCC) — the most ... Read more

November 30, 2020November 30, 2020

Opdivo Approved in Europe as Second-line Therapy for Advanced Esophageal Cancer

News

The European Commission has approved Opdivo (nivolumab) as a second-line treatment for adults with advanced inoperable, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC), who previously were treated with fluoropyrimidine and ... Read more

November 25, 2020November 25, 2020

Merck Halts Phase 3 Trial on Yervoy-Keytruda Combo in Advanced Lung Cancer

News

Merck has decided to suspend its Phase 3 trial that was assessing a combination of Yervoy (ipilimumab) and Keytruda (pembrolizumab) as a first-line therapy for patients with advanced non-small cell lung ... Read more

November 23, 2020November 24, 2020

New $100M Program Aims to Improve Diversity in Clinical Trials

News, syndicated

A new $100-million program aims to improve the diversity of participants in U.S. clinical trials with the ultimate goal of achieving better health outcomes and parity in care for underserved patient ... Read more

November 20, 2020November 20, 2020

Clinical Trial to Test CRISPR-modified T-cells in Treating Advanced Cancers

News

Immune cells that have been genetically engineered using CRISPR technology will be tested for a first time as a potential treatment of metastatic gastrointestinal cancer in a clinical trial. The Phase 1/2 ... Read more

November 18, 2020November 18, 2020

Phase 3 Study of Epcoritamab for Advanced DLBCL to Open in Europe, Australia

News

Genmab is launching a Phase 3 clinical trial investigating its bispecific antibody epcoritamab as a treatment for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) patients who fail to respond ... Read more

November 13, 2020November 13, 2020

Keytruda-Chemo Combo Improves Survival Outcomes in Advanced Lung Cancer

News

First-line treatment with a combination of Keytruda (pembrolizumab) plus chemotherapy significantly prolongs survival, and extends life without disease progression, in people with advanced non-squamous non-small cell lung cancer (NSCLC), regardless ... Read more